Literature DB >> 15316637

[Varicella-zoster virus infections].

H M Lilie1, S W Wassilew.   

Abstract

The primary infection with varicella-zoster virus (VZV) is manifest clinically as varicella. It is a common very contagious disease, normally appearing in childhood. VZV is a ubiquitous virus with a high prevalence. Clinically it is characterized by pleomorphic skin lesions. Normally antiviral therapy is necessary only in severe cases, in adults or in immunosuppressed patients. Herpes zoster, also caused by (VZV), is a neurodermal disease representing the endogenous relapse of the primary varicella infection. Herpes zoster is characterized by lesions concentrated in the innervation region of a cranial or spinal nerve. One of the most feared manifestations of herpes zoster is pain. Several antiviral drugs are approved and many studies have shown that antiviral therapy, started early in the course of disease, can significantly reduce risk and duration of postherpetic neuralgia in elderly patients. Therefore, antiviral therapy in combination with an adequate pain management should be given to all elderly patients as soon as herpes zoster is diagnosed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15316637     DOI: 10.1007/s00105-004-0789-1

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  51 in total

Review 1.  Chickenpox (varicella).

Authors:  A M Arvin
Journal:  Contrib Microbiol       Date:  1999

Review 2.  Approaches to the treatment of varicella-zoster virus infections.

Authors:  R J Whitley
Journal:  Contrib Microbiol       Date:  1999

3.  Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study.

Authors:  P J van den Broek; J W van der Meer; J D Mulder; J Versteeg; H Mattie
Journal:  Infection       Date:  1984 Sep-Oct       Impact factor: 3.553

Review 4.  Varicella zoster viral disease.

Authors:  T J Liesegang
Journal:  Mayo Clin Proc       Date:  1999-10       Impact factor: 7.616

5.  (E)-5-(2-Bromovinyl)-2'-deoxyuridine: a potent and selective anti-herpes agent.

Authors:  E De Clercq; J Descamps; P De Somer; P J Barr; A S Jones; R T Walker
Journal:  Proc Natl Acad Sci U S A       Date:  1979-06       Impact factor: 11.205

6.  Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia.

Authors:  Sawko W Wassilew; Peter Wutzler
Journal:  Antiviral Res       Date:  2003-06       Impact factor: 5.970

7.  Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo-controlled trials.

Authors:  M J Wood; R Kay; R H Dworkin; S J Soong; R J Whitley
Journal:  Clin Infect Dis       Date:  1996-02       Impact factor: 9.079

Review 8.  Varicella zoster virus latency, neurological disease and experimental models: an update.

Authors:  Randall J Cohrs; Donald H Gilden; Ravi Mahalingam
Journal:  Front Biosci       Date:  2004-01-01

Review 9.  Gabapentin: in postherpetic neuralgia.

Authors:  Monique P Curran; Antona J Wagstaff
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

10.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

View more
  2 in total

Review 1.  [Frequent and rare dermatological diseases in HIV patients].

Authors:  U R Hengge; R Mota; A Marini
Journal:  Hautarzt       Date:  2006-11       Impact factor: 0.751

Review 2.  [Important viral and bacterial infections of the skin and mucous membrane].

Authors:  A Marini; U R Hengge
Journal:  Internist (Berl)       Date:  2009-02       Impact factor: 0.743

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.